2.55
-0.19(-6.93%)
Currency In USD
| Previous Close | 2.74 |
| Open | 2.77 |
| Day High | 2.77 |
| Day Low | 2.55 |
| 52-Week High | 6.33 |
| 52-Week Low | 2.01 |
| Volume | 7.02M |
| Average Volume | 5.13M |
| Market Cap | 381.28M |
| PE | -2.68 |
| EPS | -0.95 |
| Moving Average 50 Days | 2.79 |
| Moving Average 200 Days | 3.1 |
| Change | -0.19 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $118.11 as of September 13, 2025 at a share price of $2.55. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $594.41 as of September 13, 2025 at a share price of $2.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
GlobeNewswire Inc.
Sep 11, 2025 12:00 PM GMT
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costsAUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage bio
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
GlobeNewswire Inc.
Aug 25, 2025 8:05 PM GMT
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI),
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
GlobeNewswire Inc.
Aug 07, 2025 6:00 AM GMT
Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCO